Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Expert Opinion on Emerging Drugs|December 14, 2011
Emerging oral drugs for relapsing-remitting multiple sclerosisClaudio Gasperini, Serena Ruggieri
Drug Design, Development and Therapy|August 14, 2012
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approachClaudio Gasperini, Serena Ruggieri
Therapeutic Advances in Neurological Disorders|November 15, 2013
Efficacy and safety of laquinimod in multiple sclerosis: current statusShalom Haggiag, Serena Ruggieri, Claudio Gasperini
Therapeutics and Clinical Risk Management|April 8, 2014
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosisSerena Ruggieri, Carla Tortorella, Claudio Gasperini
Expert Review of Neurotherapeutics|September 9, 2017
Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosisSerena Ruggieri, Carla Tortorella, Claudio Gasperini
Expert Opinion on Investigational Drugs|July 17, 2013
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodiesClaudio Gasperini, Shalom Haggiag, Serena Ruggieri
Therapeutics and Clinical Risk Management|September 22, 2010
Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsClaudio Gasperini, Serena Ruggieri, Carlo Pozzilli
Therapeutics and Clinical Risk Management|March 14, 2013
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimodClaudio Gasperini, Serena Ruggieri, Chiara Rosa Mancinelli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 31, 2024
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world contextLuca Prosperini, Serena Ruggieri, Shalom Haggiag, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 1, 2023
Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
Pageof 24